One of the most heartening advances in the management of COVID-19 is the development of monoclonal antibody preparations that effectively lower risk
在COVID-19管理方面最令人振奋的进展之一是开发了有效降低风险的单克隆抗体制剂
{"title":"Another Monoclonal Therapy Option for Early COVID-19","authors":"R. Ellison","doi":"10.1056/NEJM-JW.NA54243","DOIUrl":"https://doi.org/10.1056/NEJM-JW.NA54243","url":null,"abstract":"One of the most heartening advances in the management of COVID-19 is the development of monoclonal antibody preparations that effectively lower risk","PeriodicalId":19048,"journal":{"name":"NEJM Journal Watch","volume":"25 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74209493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Patients with significant left main coronary artery disease (LMCAD) traditionally have been treated with coronary artery bypass graft surgery (CABG) —
传统上，患有严重左主干冠状动脉疾病(LMCAD)的患者通常采用冠状动脉搭桥手术(CABG)治疗
{"title":"PCI vs. CABG for Left Main Coronary Artery Disease","authors":"D. Cohen","doi":"10.1056/NEJM-JW.NA54313","DOIUrl":"https://doi.org/10.1056/NEJM-JW.NA54313","url":null,"abstract":"Patients with significant left main coronary artery disease (LMCAD) traditionally have been treated with coronary artery bypass graft surgery (CABG) —","PeriodicalId":19048,"journal":{"name":"NEJM Journal Watch","volume":"130 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82930987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Major aims in the treatment of hemophilia A include reducing bleeding events, avoiding severe arthropathy, and improving quality of life. Among the
血友病A治疗的主要目的包括减少出血事件，避免严重的关节病变，提高生活质量。在
{"title":"Longer-Term Follow-Up in Patients Receiving AAV Gene Therapy for Hemophilia A","authors":"B. Stein, Mhs","doi":"10.1056/NEJM-JW.NA54280","DOIUrl":"https://doi.org/10.1056/NEJM-JW.NA54280","url":null,"abstract":"Major aims in the treatment of hemophilia A include reducing bleeding events, avoiding severe arthropathy, and improving quality of life. Among the","PeriodicalId":19048,"journal":{"name":"NEJM Journal Watch","volume":"51 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80394856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Studies with various limitations generally have shown that high sodium intake and low potassium intake are associated with higher risk for hypertension
有各种局限性的研究普遍表明，高钠摄入和低钾摄入与高血压的高风险相关
{"title":"Further Evidence to Support a Low-Sodium, High-Potassium Diet","authors":"A. Brett","doi":"10.1056/NEJM-JW.NA54291","DOIUrl":"https://doi.org/10.1056/NEJM-JW.NA54291","url":null,"abstract":"Studies with various limitations generally have shown that high sodium intake and low potassium intake are associated with higher risk for hypertension","PeriodicalId":19048,"journal":{"name":"NEJM Journal Watch","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75431977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sponsoring Organization: American Academy of Pediatrics (AAP)BackgroundThe AAP annually reviews its recommendations for routine influenza immunization;
主办机构:美国儿科学会(AAP)背景AAP每年审查其常规流感免疫的建议;
{"title":"Influenza Vaccination in Children: Recommendations for the 2021–2022 Season","authors":"D. Lehman","doi":"10.1056/NEJM-JW.NA54091","DOIUrl":"https://doi.org/10.1056/NEJM-JW.NA54091","url":null,"abstract":"Sponsoring Organization: American Academy of Pediatrics (AAP)BackgroundThe AAP annually reviews its recommendations for routine influenza immunization;","PeriodicalId":19048,"journal":{"name":"NEJM Journal Watch","volume":"37 1-2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82671428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Evidence suggests that shorter courses of systemic corticosteroids are preferable for patients hospitalized with acute exacerbations of chronic
有证据表明，较短疗程的全身性皮质类固醇治疗对慢性炎症急性加重住院的患者更可取
{"title":"Should Steroid Dosing in COPD Exacerbations Be Individualized","authors":"N. Winawer, Sfhm","doi":"10.1056/NEJM-JW.NA54315","DOIUrl":"https://doi.org/10.1056/NEJM-JW.NA54315","url":null,"abstract":"Evidence suggests that shorter courses of systemic corticosteroids are preferable for patients hospitalized with acute exacerbations of chronic","PeriodicalId":19048,"journal":{"name":"NEJM Journal Watch","volume":"17 1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76043617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Little is known about long-term outcomes in patients with neuropathy and neurofascin-155 immunoglobulin G4 (NF155-IgG4) antibodies, and even less about
{"title":"Neuropathy with Neurofascin-155 Immunoglobulins: Clinical Profile and Prognosis","authors":"Leana Doherty","doi":"10.1056/NEJM-JW.NA54230","DOIUrl":"https://doi.org/10.1056/NEJM-JW.NA54230","url":null,"abstract":"Little is known about long-term outcomes in patients with neuropathy and neurofascin-155 immunoglobulin G4 (NF155-IgG4) antibodies, and even less about","PeriodicalId":19048,"journal":{"name":"NEJM Journal Watch","volume":"24 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81960796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sponsoring Organizations: Society of Critical Care Medicine (SCCM); European Society of Intensive Care Medicine (ESICM)BackgroundThis is the fourth
主办单位:重症医学会(SCCM);欧洲重症医学会(ESICM)背景:这是第四届
{"title":"New Surviving Sepsis Guidelines","authors":"P. Kritek","doi":"10.1056/NEJM-JW.NA54288","DOIUrl":"https://doi.org/10.1056/NEJM-JW.NA54288","url":null,"abstract":"Sponsoring Organizations: Society of Critical Care Medicine (SCCM); European Society of Intensive Care Medicine (ESICM)BackgroundThis is the fourth","PeriodicalId":19048,"journal":{"name":"NEJM Journal Watch","volume":"28 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83697662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Current guidelines recommend targeted temperature management between 32°C and 36°C for a minimum of 24 hours in all comatose patients with return of
目前的指南建议在所有恢复昏迷的患者中，将目标温度控制在32°C至36°C之间至少24小时
{"title":"In Comatose Survivors of Out-of-Hospital-Cardiac Arrest, Colder Isn't Better","authors":"A. Calderon, Facp., Sfhm","doi":"10.1056/NEJM-JW.NA54209","DOIUrl":"https://doi.org/10.1056/NEJM-JW.NA54209","url":null,"abstract":"Current guidelines recommend targeted temperature management between 32°C and 36°C for a minimum of 24 hours in all comatose patients with return of","PeriodicalId":19048,"journal":{"name":"NEJM Journal Watch","volume":"286 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73476431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Standard chemotherapy agents for advanced biliary cancer are gemcitabine and cisplatin. Recent data suggest a modest benefit for use of second-line
晚期胆道癌的标准化疗药物是吉西他滨和顺铂。最近的数据显示，使用二线治疗有一定的益处
{"title":"FOLFIRINOX Not Better Than Gemcitabine-Cisplatin in Biliary Cancer","authors":"D. Ilson","doi":"10.1056/NEJM-JW.NA54286","DOIUrl":"https://doi.org/10.1056/NEJM-JW.NA54286","url":null,"abstract":"Standard chemotherapy agents for advanced biliary cancer are gemcitabine and cisplatin. Recent data suggest a modest benefit for use of second-line","PeriodicalId":19048,"journal":{"name":"NEJM Journal Watch","volume":"15 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89041944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：